Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.

@article{Howell1996PharmacokineticsPA,
  title={Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.},
  author={Anthony Howell and David J Defriend and J. F. R. Robertson and Roger W. Blamey and Linda Anderson and Elizabeth Garratt Anderson and F. A. Sutcliffe and Paul Walton},
  journal={British Journal of Cancer},
  year={1996},
  volume={74},
  pages={300 - 308}
}
We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen. The agent was administered as a monthly depot intramuscular injection. Peak levels of ICI 182780 occurred a median of 8-9 days after dosing and then declined but were above the projected therapeutic threshold at day 28. Cmax during the first month was 10.5 ng/ml-1 and during the sixth month was 12.6… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 77 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Inhibition of EGF - receptor tyrosine klinase activity by 4 - aniloquinazolines . ( abstract 6 . 6 )

  • BR WESTLEY
  • Br . J . Cancer
  • 1994

Pure anti - oestrogens ( ICI 164384 and ICI 182780 ) and breast cancer : is the attainment of complete oestrogen withdrawal worthwhile ?

  • RI NICHOLSON, AB FRANCIS, RA MCCLELLAND, MANNING DL AND GEE JMW
  • Endocrine Related Cancer
  • 1994

Similar Papers

Loading similar papers…